LBA3_PR gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)
Timeline
Attention over time
Attention Score history
Login
to access the full charts related to this output.
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2016.
All research outputs
#5,405,871
of 27,788,362 outputs
Outputs from Annals of Oncology
#3,027
of 8,888 outputs
Outputs of similar age
#73,384
of 315,163 outputs
Outputs of similar age from Annals of Oncology
#60
of 260 outputs
Altmetric has tracked 27,788,362 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,888 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.9. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,163 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 260 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
